L. Butterfield, M. Disis, B. Fox, P. Lee, S. Khleif et al., A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers", Journal of Translational Medicine, vol.6, issue.1, 2008.
DOI : 10.1186/1479-5876-6-81

D. Chaussabel, chaussabel/tracking-scientific-con tent-in-knol, Tracking Scientific Content in Knol. Knol, 2009.

R. Simon, Development and Evaluation of Therapeutically Relevant Predictive Classifiers Using Gene Expression Profiling, JNCI Journal of the National Cancer Institute, vol.98, issue.17, pp.1169-1171, 2006.
DOI : 10.1093/jnci/djj364

R. Simon, Validation of pharmacogenomic biomarker classifiers for treatment selection, Cancer Biomarkers, vol.2, issue.3-4, pp.89-96, 2006.
DOI : 10.3233/CBM-2006-23-402

R. Simon, Development and validation of biomarker classifiers for treatment selection, Journal of Statistical Planning and Inference, vol.138, issue.2, pp.308-320, 2008.
DOI : 10.1016/j.jspi.2007.06.010

R. Simon, Lost in translation: Problems and pitfalls in translating laboratory observations to clinical utility, European Journal of Cancer, vol.44, issue.18, pp.2707-2713, 2008.
DOI : 10.1016/j.ejca.2008.09.009

M. Dudley, J. Yang, R. Sherry, M. Hughes, R. Royal et al., FDA: CBER/Guidances/Guidlines/Points to consider, 2009.

A. Harzstark and C. Ryan, Therapies in development for castrate-resistant prostate cancer, Expert Review of Anticancer Therapy, vol.8, issue.2, pp.259-268, 2008.
DOI : 10.1586/14737140.8.2.259

C. Fraser, Biological Variation: from Principles to Practice, 2001.

C. Fraser, Reference change values: the way forward in monitoring, Annals of Clinical Biochemistry, vol.46, issue.3, pp.264-265, 2009.
DOI : 10.1258/acb.2009.009006

B. Comin-anduix, A. Gualberto, J. Glaspy, E. Seja, M. Ontiveros et al., Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays, Clinical Cancer Research, vol.12, issue.1, pp.107-116, 2006.
DOI : 10.1158/1078-0432.CCR-05-0136

B. Comin-anduix, Y. Lee, J. Jalil, A. Algazi, R. De-la et al., Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma, Journal of Translational Medicine, vol.6, issue.1, p.22, 2008.
DOI : 10.1186/1479-5876-6-22

M. Davis, A Prescription for Human Immunology, Immunity, vol.29, issue.6, pp.835-838, 2008.
DOI : 10.1016/j.immuni.2008.12.003

M. Berg, A. Lundqvist, P. Mccoy, . Jr, L. Samsel et al., Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells, Cytotherapy, vol.11, issue.3, pp.341-355, 2009.
DOI : 10.1080/14653240902807034
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736058

E. Von-euw, T. Chodon, N. Attar, J. Jalil, and R. Koya, CTLA4 blockade increases Th17 cells in patients with metastatic melanoma, Journal of Translational Medicine, vol.7, issue.1, p.35, 2009.
DOI : 10.1186/1479-5876-7-35

. Monsurro-'v, E. Wang, Y. Yamano, S. Migueles, M. Panelli et al., Quiescent phenotype of tumor-specific CD8+ T cells following immunization, Blood, vol.104, issue.7, pp.1970-1978, 2004.
DOI : 10.1182/blood-2004-02-0525

S. Kuerten, T. Nowacki, T. Kleen, R. Asaad, P. Lehmann et al., Cells in HIV Infection, AIDS Research and Human Retroviruses, vol.24, issue.1, pp.62-71, 2008.
DOI : 10.1089/aid.2007.0125

. Monsurro-'v, D. Nagorsen, E. Wang, M. Provenzano, M. Dudley et al., Functional Heterogeneity of Vaccine-Induced CD8+ T Cells, The Journal of Immunology, vol.168, issue.11, pp.5933-5942, 2002.
DOI : 10.4049/jimmunol.168.11.5933

K. Shafer-weaver, T. Sayers, S. Strobl, E. Derby, T. Ulderich et al., The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity, Journal of Translational Medicine, vol.1, issue.1, p.14, 2003.
DOI : 10.1186/1479-5876-1-14

K. Shafer-weaver, S. Rosenberg, S. Strobl, A. Gregory, M. Baseler et al., Application of the Granzyme B ELISPOT Assay for Monitoring Cancer Vaccine Trials, Journal of Immunotherapy, vol.29, issue.3, pp.328-335, 2006.
DOI : 10.1097/01.cji.0000203079.35612.c8

A. Malyguine, S. Strobl, L. Zaritskaya, M. Baseler, and K. Shafer-weaver, New Approaches for Monitoring CTL Activity in Clinical Trials, Adv Exp Med Biol, vol.601, pp.273-284, 2007.
DOI : 10.1007/978-0-387-72005-0_29

L. Zaritskaya, K. Shafer-weaver, M. Gregory, S. Strobl, M. Baseler et al., Application of a Flow Cytometric Cytotoxicity Assay for Monitoring Cancer Vaccine Trials, Journal of Immunotherapy, vol.32, issue.2, pp.186-194, 2009.
DOI : 10.1097/CJI.0b013e318197b1b2

S. Kaech, S. Hemby, E. Kersh, and R. Ahmed, Molecular and Functional Profiling of Memory CD8 T Cell Differentiation, Cell, vol.111, issue.6, pp.837-851, 2002.
DOI : 10.1016/S0092-8674(02)01139-X

T. Nowacki, S. Kuerten, W. Zhang, C. Shive, C. Kreher et al., Granzyme B production distinguishes recently activated CD8+ memory cells from resting memory cells, Cellular Immunology, vol.247, issue.1, pp.36-48, 2007.
DOI : 10.1016/j.cellimm.2007.07.004

T. Schlingmann, C. Shive, O. Targoni, M. Tary-lehmann, and P. Lehmann, Increased per cell IFN-gamma productivity indicates recent in vivo activation of T cells, Cell Immunol, 2009.

M. Panelli, B. Martin, D. Nagorsen, E. Wang, K. Smith et al., A Genomic- and Proteomic-Based Hypothesis on the Eclectic Effects of Systemic Interleukin-2 Administration in the Context of Melanoma-Specific Immunization, Cells Tissues Organs, vol.177, issue.3, pp.124-131, 2003.
DOI : 10.1159/000079986

E. Wang, M. Panelli, and F. Marincola, Gene profiling of immune responses against tumors, Current Opinion in Immunology, vol.17, issue.4, pp.423-427, 2005.
DOI : 10.1016/j.coi.2005.05.007

E. Wang, M. Panelli, and F. Marincola, Autologous Tumor Rejection in Humans: Trimming the Myths, Immunological Investigations, vol.1, issue.3, pp.437-458, 2006.
DOI : 10.4049/jimmunol.168.9.4272

P. Dubey, H. Su, N. Adonai, S. Du, A. Rosato et al., Quantitative imaging of the T cell antitumor response by positron-emission tomography, Proceedings of the National Academy of Sciences, vol.100, issue.3, pp.1232-1237, 2003.
DOI : 10.1073/pnas.0337418100

A. Wu and P. Senter, Arming antibodies: prospects and challenges for immunoconjugates, Nature Biotechnology, vol.90, issue.9
DOI : 10.1021/bc050039z

C. Radu, C. Shu, E. Nair-gill, S. Shelly, J. Barrio et al., Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2???-deoxycytidine analog, Nature Medicine, vol.2, issue.7, pp.783-788, 2008.
DOI : 10.1038/nm1724

P. Tumeh and C. Radu, PET Imaging of Cancer Immunotherapy, Journal of Nuclear Medicine, vol.49, issue.6, pp.865-868, 2008.
DOI : 10.2967/jnumed.108.051342

L. Platanias, Mechanisms of type-I- and type-II-interferon-mediated signalling, Nature Reviews Immunology, vol.132, issue.5, pp.375-386, 2005.
DOI : 10.1001/jama.290.24.3222

S. Kaur, A. Sassano, B. Dolniak, S. Joshi, B. Majchrzak-kita et al., Role of the Akt pathway in mRNA translation of interferon-stimulated genes, Proceedings of the National Academy of Sciences, vol.105, issue.12, pp.4808-4813, 2008.
DOI : 10.1073/pnas.0710907105

C. Schindler and C. Plumlee, Inteferons pen the JAK???STAT pathway, Seminars in Cell & Developmental Biology, vol.19, issue.4, pp.311-318, 2008.
DOI : 10.1016/j.semcdb.2008.08.010

J. Wulfkuhle, L. Liotta, and E. Petricoin, Early detection: Proteomic applications for the early detection of cancer, Nature Reviews Cancer, vol.3, issue.4, pp.267-275, 2003.
DOI : 10.1038/nrc1043

J. Wulfkuhle, C. Paweletz, P. Steeg, E. Petricoin, and L. Liotta, Proteomic Approaches to the Diagnosis, Treatment, and Monitoring of Cancer, Adv Exp Med Biol, vol.532, pp.59-68, 2003.
DOI : 10.1007/978-1-4615-0081-0_7

J. Wulfkuhle, R. Speer, M. Pierobon, J. Laird, V. Espina et al., Multiplexed Cell Signaling Analysis of Human Breast Cancer Applications for Personalized Therapy, Journal of Proteome Research, vol.7, issue.4, pp.1508-1517, 2008.
DOI : 10.1021/pr7008127

G. Nolan, S. Fiering, J. Nicolas, and L. Herzenberg, Fluorescence-activated cell analysis and sorting of viable mammalian cells based on beta-D-galactosidase activity after transduction of Escherichia coli lacZ., Proceedings of the National Academy of Sciences, vol.85, issue.8, pp.2603-2607, 1998.
DOI : 10.1073/pnas.85.8.2603

K. Marks and G. Nolan, Chemical labeling strategies for cell biology, Nature Methods, vol.16, issue.8, pp.591-596, 2006.
DOI : 10.1038/nmeth906

V. Espina, K. Edmiston, M. Heiby, M. Pierobon, M. Sciro et al., A Portrait of Tissue Phosphoprotein Stability in the Clinical Tissue Procurement Process, Molecular & Cellular Proteomics, vol.7, issue.10, pp.1998-2018, 2008.
DOI : 10.1074/mcp.M700596-MCP200

A. Dash, I. Maine, S. Varambally, R. Shen, A. Chinnaiyan et al., Changes in Differential Gene Expression because of Warm Ischemia Time of Radical Prostatectomy Specimens, The American Journal of Pathology, vol.161, issue.5, pp.1743-1748, 2002.
DOI : 10.1016/S0002-9440(10)64451-3

C. Longo, A. Patanarut, T. George, B. Bishop, W. Zhou et al., Core-Shell Hydrogel Particles Harvest, Concentrate and Preserve Labile Low Abundance Biomarkers, PLoS ONE, vol.177, issue.3, p.4763, 2009.
DOI : 10.1371/journal.pone.0004763.s001
URL : http://doi.org/10.1371/journal.pone.0004763

M. Panelli, W. Rljr, M. Foster, B. Martin, E. Wang et al., Forecasting the cytokine storm following systemic interleukin-2 administration, Journal of Translational Medicine, vol.2, issue.1, p.17, 2004.
DOI : 10.1186/1479-5876-2-17

L. Rossi, B. Martin, G. Hortin, W. Rljr, M. Foster et al., Inflammatory protein profile during systemic high dose interleukin-2 administration, PROTEOMICS, vol.24, issue.2, pp.709-720, 2006.
DOI : 10.1002/pmic.200500004

C. Sarkar and D. Lauffenburger, Cell-Level Pharmacokinetic Model of Granulocyte Colony-Stimulating Factor: Implications for Ligand Lifetime and Potency in Vivo, Molecular Pharmacology, vol.63, issue.1, pp.147-158, 2003.
DOI : 10.1124/mol.63.1.147

J. Apgar, J. Toettcher, D. Endy, F. White, and B. Tidor, Stimulus Design for Model Selection and Validation in Cell Signaling, PLoS Computational Biology, vol.21, issue.2, p.30, 2008.
DOI : 10.1371/journal.pcbi.0040030.sg003

D. Chaussabel, C. Quinn, J. Shen, P. Patel, C. Glaser et al., A Modular Analysis Framework for Blood Genomics Studies: Application to Systemic Lupus Erythematosus, Immunity, vol.29, issue.1, pp.150-164, 2008.
DOI : 10.1016/j.immuni.2008.05.012

E. Wang and F. Marincola, Bottom Up: A Modular View of Immunology, Immunity, vol.29, issue.1, pp.9-11, 2008.
DOI : 10.1016/j.immuni.2008.07.002

P. Jin and E. Wang, Polymorphism in clinical immunology. From HLA typing to immunogenetic profiling, Journal of Translational Medicine, vol.1, issue.1, p.8, 2003.
DOI : 10.1186/1479-5876-1-8

E. Wang, A. Worschech, and F. Marincola, The immunologic constant of rejection, Trends in Immunology, vol.29, issue.6, pp.256-262, 2008.
DOI : 10.1016/j.it.2008.03.002

J. Salk, IMMUNOLOGICAL PARADOXES: THEORETICAL CONSIDERATIONS IN THE REJECTION OR RETENTION OF GRAFTS, TUMORS, AND NORMAL TISSUE, Annals of the New York Academy of Sciences, vol.130, issue.3287, pp.365-380, 1969.
DOI : 10.1002/path.1700860225

A. Mantovani, P. Romero, A. Palucka, and F. Marincola, Tumour immunity: effector response to tumour and role of the microenvironment, The Lancet, vol.371, issue.9614, pp.771-783, 2008.
DOI : 10.1016/S0140-6736(08)60241-X

E. Wang, A. Albini, D. Stroncek, and F. Marincola, New take on comparative immunology: relevance to immunotherapy, Immunotherapy, vol.1, issue.3, pp.355-366, 2009.
DOI : 10.2217/imt.09.10

E. Wang, A. Monaco, . Monsurro-'v, M. Sabatino, Z. Pos et al., Antitumor vaccines , immunotherapy and the immunological constant of rejection, IDrugs, vol.12, pp.297-301, 2009.

E. Wang, L. Miller, G. Ohnmacht, S. Mocellin, D. Petersen et al., Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness, Cancer Res, vol.62, pp.3581-3586, 2002.

C. Bigger, K. Brasky, and R. Lanford, DNA Microarray Analysis of Chimpanzee Liver during Acute Resolving Hepatitis C Virus Infection, Journal of Virology, vol.75, issue.15, pp.7059-7066, 2001.
DOI : 10.1128/JVI.75.15.7059-7066.2001

D. Bowen and C. Walker, Adaptive immune responses in acute and chronic hepatitis C virus infection, Nature, vol.38, issue.7053, pp.946-952, 2005.
DOI : 10.1128/JVI.78.3.1575-1581.2004

C. Bigger, B. Guerra, K. Brasky, G. Hubbard, M. Beard et al., Intrahepatic Gene Expression during Chronic Hepatitis C Virus Infection in Chimpanzees, Journal of Virology, vol.78, issue.24, pp.13779-13792, 2004.
DOI : 10.1128/JVI.78.24.13779-13792.2004

M. Sarwal, M. Chua, N. Kambham, S. Hsieh, T. Satterwhite et al., Molecular Heterogeneity in Acute Renal Allograft Rejection Identified by DNA Microarray Profiling, New England Journal of Medicine, vol.349, issue.2, pp.125-138, 2003.
DOI : 10.1056/NEJMoa035588

L. Bennett, A. Palucka, E. Arce, V. Cantrell, J. Borvak et al., Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood, The Journal of Experimental Medicine, vol.149, issue.6
DOI : 10.1136/ard.58.5.309

V. Pascual, L. Farkas, and J. Banchereau, Systemic lupus erythematosus: all roads lead to type I interferons, Current Opinion in Immunology, vol.18, issue.6, pp.676-682, 2006.
DOI : 10.1016/j.coi.2006.09.014

F. Pages, A. Berger, M. Camus, F. Sanchez-cabo, A. Costes et al., Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer, New England Journal of Medicine, vol.353, issue.25, pp.2654-2666, 2005.
DOI : 10.1056/NEJMoa051424

J. Galon, A. Costes, F. Sanchez-cabo, A. Kirilovsky, B. Mlecnik et al., Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome, Science, vol.313, issue.5795, pp.1960-1964, 2006.
DOI : 10.1126/science.1129139

J. Galon and W. Fridman, The Adaptive Immunologic Microenvironment in Colorectal Cancer: A Novel Perspective, Cancer Research, vol.67, issue.5, pp.1883-1886, 2007.
DOI : 10.1158/0008-5472.CAN-06-4806

A. Shanker, G. Verdeil, M. Buferne, E. Inderberg-suso, D. Puthier et al., CD8 T Cell Help for Innate Antitumor Immunity, The Journal of Immunology, vol.179, issue.10, pp.6651-6662, 2007.
DOI : 10.4049/jimmunol.179.10.6651
URL : https://hal.archives-ouvertes.fr/hal-00297261

A. Worschech, N. Chen, Y. Yu, Q. Zhang, Z. Pos et al., Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy, BMC Genomics, vol.10, issue.1, 2009.
DOI : 10.1186/1471-2164-10-301

A. Abati, J. Sanford, P. Fetsch, F. Marincola, and S. Wolman, Fluorescence in situ hybridization (fish): A user's guide to optimal preparation of cytologic specimens, Diagnostic Cytopathology, vol.90, issue.5, pp.486-492, 1995.
DOI : 10.1002/dc.2840130518

K. Honda and T. Taniguchi, IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors, Nature Reviews Immunology, vol.264, issue.9, pp.644-658, 2006.
DOI : 10.1038/nri1900

A. Paun and P. Pitha, The IRF family, revisited, Biochimie, vol.89, issue.6-7, pp.744-753, 2007.
DOI : 10.1016/j.biochi.2007.01.014

M. Camus, M. Tosolini, B. Mlecnik, F. Pages, A. Kirilovsky et al., Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence, Cancer Research, vol.69, issue.6, pp.2685-2693, 2009.
DOI : 10.1158/0008-5472.CAN-08-2654

F. Balkwill and A. Mantovani, Inflammation and cancer: back to Virchow? Lancet, pp.539-545, 2001.

F. Balkwill, K. Charles, and A. Mantovani, Smoldering and polarized inflammation in the initiation and promotion of malignant disease, Cancer Cell, vol.7, issue.3, pp.211-217, 2005.
DOI : 10.1016/j.ccr.2005.02.013

L. Coussens and Z. Werb, Inflammation and cancer, Nature, vol.2, issue.6917, pp.860-867, 2002.
DOI : 10.1006/cyto.1996.0074

D. Visser, K. Korets, L. Coussens, and L. , De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent, Cancer Cell, vol.7, issue.5, pp.411-423, 2005.
DOI : 10.1016/j.ccr.2005.04.014

T. Gajewski, Y. Meng, C. Blank, I. Brown, A. Kacha et al., Immune resistance orchestrated by the tumor microenvironment, Immunological Reviews, vol.5, issue.1, pp.131-145, 2006.
DOI : 10.1016/j.drup.2005.03.002

E. Wang and F. Marincola, A natural history of melanoma: serial gene expression analysis, Immunology Today, vol.21, issue.12, pp.619-623, 2000.
DOI : 10.1016/S0167-5699(00)01724-2

E. Wang, M. Panelli, . Monsurro-'v, and F. Marincola, Gene expression profiling of anti-cancer immune responses, Curr Op Mol Ther, vol.6, pp.288-295, 2004.

E. Wang, S. Selleri, M. Sabatino, A. Monaco, Z. Pos et al., Spontaneous and treatment-induced cancer rejection in humans, Expert Opinion on Biological Therapy, vol.16, issue.3, pp.337-349, 2008.
DOI : 10.1007/s00018-007-7186-8

A. Worschech, D. Haddad, D. Stroncek, E. Wang, F. Marincola et al., The immunologic aspects of poxvirus oncolytic therapy, Cancer Immunology, Immunotherapy, vol.6, issue.9, 2009.
DOI : 10.1007/s00262-009-0686-7

L. Rivino, M. Messi, D. Jarrossay, A. Lanzavecchia, F. Sallusto et al., Central Memory T Cells, The Journal of Experimental Medicine, vol.2, issue.6, pp.725-735, 2004.
DOI : 10.1086/320996

T. Sorensen, Targeting the Chemokine Receptor CXCR3 and Its Ligand CXCL10 in the Central Nervous System: Potential Therapy for Inflammatory Demyelinating Disease?, Current Neurovascular Research, vol.1, issue.2, pp.183-190, 2004.
DOI : 10.2174/1567202043480143

E. Heller, E. Liu, A. Tager, Q. Yuan, A. Lin et al., Chemokine CXCL10 Promotes Atherogenesis by Modulating the Local Balance of Effector and Regulatory T Cells, Circulation, vol.113, issue.19, pp.2301-2312, 2006.
DOI : 10.1161/CIRCULATIONAHA.105.605121

W. Hancock, W. Gao, V. Csizmadia, K. Faia, N. Shemmeri et al., Donor-Derived Ip-10 Initiates Development of Acute Allograft Rejection, The Journal of Experimental Medicine, vol.51, issue.8, pp.975-980, 2001.
DOI : 10.1074/jbc.271.39.24286

Z. Zhang, L. Kaptanoglu, Y. Tang, D. Ivancic, S. Rao et al., IP-10-induced recruitment of CXCR3+ host T cells is required for small bowel allograft rejection, Gastroenterology, vol.126, issue.3, pp.809-818, 2004.
DOI : 10.1053/j.gastro.2003.12.014

I. Mullins, C. Slingluff, J. Lee, C. Garbee, J. Shu et al., CXC Chemokine Receptor 3 Expression by Activated CD8+ T cells Is Associated with Survival in Melanoma Patients with Stage III Disease, Cancer Research, vol.64, issue.21, pp.7697-7701, 2004.
DOI : 10.1158/0008-5472.CAN-04-2059

M. Kunz, A. Toksoy, M. Goebeler, E. Engelhardt, E. Brocker et al., Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma, The Journal of Pathology, vol.155, issue.4, pp.552-558, 1999.
DOI : 10.1002/(SICI)1096-9896(199912)189:4<552::AID-PATH469>3.0.CO;2-I

C. Monteagudo, J. Martin, E. Jorda, and . Llombart-bosch, CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors, Journal of Clinical Pathology, vol.60, issue.6, pp.596-599, 2007.
DOI : 10.1136/jcp.2005.032144

H. Harlin, Y. Meng, A. Peterson, Y. Zha, M. Tretiakova et al., Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment, Cancer Research, vol.69, issue.7, pp.3077-3085, 2009.
DOI : 10.1158/0008-5472.CAN-08-2281

S. Ugurel, D. Schrama, G. Keller, D. Schadendorf, E. Brocker et al., Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy, Cancer Immunology, Immunotherapy, vol.24, issue.5, pp.685-691, 2007.
DOI : 10.1007/s00262-007-0407-z

P. Kalinski, J. Urban, R. Narang, E. Berk, E. Wieckowski et al., Dendritic cell-based therapeutic cancer vaccines: what we have and what we need, Future Oncology, vol.5, issue.3, pp.379-390, 2009.
DOI : 10.2217/fon.09.6
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713774

R. Muthuswamy, J. Urban, J. Lee, T. Reinhart, D. Bartlett et al., Ability of Mature Dendritic Cells to Interact with Regulatory T Cells Is Imprinted during Maturation, Cancer Research, vol.68, issue.14, pp.5972-5978, 2008.
DOI : 10.1158/0008-5472.CAN-07-6818

R. Critchley-thorne, D. Simons, N. Yan, A. Miyahira, F. Dirbas et al., Impaired interferon signaling is a common immune defect in human cancer, Proceedings of the National Academy of Sciences, vol.106, issue.22, pp.9010-9015, 2009.
DOI : 10.1073/pnas.0901329106

S. Selleri, S. Deola, Z. Pos, J. P. Worschech, A. Slezak et al., GM-CSF/IL-3/IL-5 receptor common ?? chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T cells, Journal of Translational Medicine, vol.6, issue.1, p.17, 2008.
DOI : 10.1186/1479-5876-6-17

A. Zea, B. Curti, D. Longo, W. Alvord, S. Strobl et al., Alterations in T cell receptor and signal transduction molecules in melanoma patients, Clin Cancer Res, vol.1, pp.1327-1335, 1995.

P. Rodriguez and A. Ochoa, T cell dysfunction in cancer: Role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress, Seminars in Cancer Biology, vol.16, issue.1, pp.66-72, 2006.
DOI : 10.1016/j.semcancer.2005.10.001

L. Norian, P. Rodriguez, O. Mara, L. Zabaleta, J. Ochoa et al., Tumor-Infiltrating Regulatory Dendritic Cells Inhibit CD8+ T Cell Function via L-Arginine Metabolism, Cancer Research, vol.69, issue.7, pp.3086-3094, 2009.
DOI : 10.1158/0008-5472.CAN-08-2826
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848068

W. Leonard, O. Shea, and J. , JAKS AND STATS: Biological Implications, Annual Review of Immunology, vol.16, issue.1, pp.293-322, 1998.
DOI : 10.1146/annurev.immunol.16.1.293

A. Heriot, J. Marriott, S. Cookson, D. Kumar, and A. Dalgleish, Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection, British Journal of Cancer, vol.82, issue.5, pp.1009-1012, 2000.
DOI : 10.1054/bjoc.1999.1034

F. Marincola, E. Wang, M. Herlyn, B. Seliger, and S. Ferrone, Tumors as elusive targets of T-cell-based active immunotherapy, Trends in Immunology, vol.24, issue.6, pp.335-342, 2003.
DOI : 10.1016/S1471-4906(03)00116-9

. Monsurro-'v, S. Beghelli, R. Wang, S. Barbi, S. Coin et al., Anti-viral status segregates two pancreatic adenocarcinoma molecular phenotypes with potential relevance for adenoviral gene therapy, 2009.

S. Mandruzzato, A. Callegaro, G. Turcatel, S. Francescato, M. Montesco et al., A gene expression signature associated with survival in metastatic melanoma, Journal of Translational Medicine, vol.4, issue.1, p.50, 2006.
DOI : 10.1186/1479-5876-4-50

M. Bittner, P. Meltzer, Y. Chen, E. Jiang, E. Seftor et al., Molecular classification of cutaneous malignant melanoma by gene expression: shifting from a countinuous spectrum to distinct biologic entities, Nature, vol.406, issue.6795, pp.536-840, 2000.
DOI : 10.1038/35020115

C. Haqq, M. Nosrati, D. Sudilovsky, J. Crothers, D. Khodabakhsh et al., The gene expression signatures of melanoma progression, Proceedings of the National Academy of Sciences, vol.102, issue.17, pp.6092-6097, 2005.
DOI : 10.1073/pnas.0501564102

M. Kashani-sabet, J. Rangel, S. Torabian, M. Nosrati, J. Simko et al., A multi-marker assay to distinguish malignant melanomas from benign nevi, Proceedings of the National Academy of Sciences, vol.106, issue.15, pp.6268-6272, 2009.
DOI : 10.1073/pnas.0901185106

T. Hocker, M. Singh, and H. Tsao, Melanoma Genetics and Therapeutic Approaches in the 21st Century: Moving from the Benchside to the Bedside, Journal of Investigative Dermatology, vol.128, issue.11, pp.2575-2595, 2008.
DOI : 10.1038/jid.2008.226

Y. Kawakami, H. Sumimoto, T. Fujita, and Y. Matsuzaki, Immunological detection of altered signaling molecules involved in melanoma development, Cancer and Metastasis Reviews, vol.9, issue.2, pp.357-366, 2005.
DOI : 10.1007/s10555-005-1583-y

E. Wang, S. Voiculescu, L. Poole, I. Gamil, M. Li et al., Clonal Persistence and Evolution During a Decade of Recurrent Melanoma, Journal of Investigative Dermatology, vol.126, issue.6, pp.1372-1377, 2006.
DOI : 10.1038/sj.jid.5700193

M. Sabatino, Y. Zhao, S. Voiculescu, A. Monaco, P. Robbins et al., Conservation of a core of genetic alterations over a decade of recurrent melanoma supports the melanoma stem cell hypothesis, Cancer Res, vol.68, pp.222-231, 2008.

B. Rubinfeld, P. Robbins, M. Gamil, I. Albert, E. Porfiri et al., Stabilization of beta -Catenin by Genetic Defects in Melanoma Cell Lines, Science, vol.275, issue.5307, pp.1790-1792, 1997.
DOI : 10.1126/science.275.5307.1790

P. Robbins, M. Kawakami, Y. Stevens, E. Yannelli, J. Rosenberg et al., Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy [published erratum appears in Cancer Res, Jul Cancer Res, vol.1554, issue.54, pp.39523124-3126, 1994.

S. Mocellin, G. Ohnmacht, E. Wang, and F. Marincola, Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness, International Journal of Cancer, vol.165, issue.2, pp.236-242, 2001.
DOI : 10.1002/ijc.1328

S. Mocellin, E. Wang, and F. Marincola, Cytokines and Immune Response in the Tumor Microenvironment, Journal of Immunotherapy, vol.24, issue.5, pp.392-407, 2001.
DOI : 10.1097/00002371-200109000-00002

S. Mocellin, M. Panelli, E. Wang, D. Nagorsen, and F. Marincola, The dual role of IL-10, Trends in Immunology, vol.24, issue.1, pp.36-43, 2002.
DOI : 10.1016/S1471-4906(02)00009-1

Y. Li, C. Hu, Q. Shao, M. Huang, J. Hou et al., Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma, Journal of Translational Medicine, vol.6, issue.1, p.1, 2008.
DOI : 10.1186/1479-5876-6-1

K. Lo, K. To, and D. Huang, Focus on nasopharyngeal carcinoma, Cancer Cell, vol.5, issue.5, pp.423-428, 2004.
DOI : 10.1016/S1535-6108(04)00119-9

A. Mcdermott, S. Dutt, and J. Watkinson, The aetiology of nasopharyngeal carcinoma, Clinical Otolaryngology and Allied Sciences, vol.2, issue.2, pp.82-92, 2001.
DOI : 10.1016/S0140-6736(85)90861-X

M. Simons, HLA and nasopharyngeal carcinoma: 30 years on, ASHI Quarterly, vol.27, pp.52-55, 2003.

J. Burgos, Involvement of the Epstein???Barr Virus in the Nasopharyngeal Carcinoma Pathogenesis, Medical Oncology, vol.22, issue.2, pp.113-121, 2005.
DOI : 10.1385/MO:22:2:113

M. Simons, N. Day, G. Wee, K. Shanmugaratnam, H. Ho et al., Nasopharyngeal carcinoma V: immunogenetic studies of Southeast Asian ethnic groups with high and low risk for the tumor, Cancer Res, vol.34, pp.1192-1195, 1974.

S. Lee, A. Chan, S. Cheung, W. Thomas, D. Croom-carter et al., CTL Control of EBV in Nasopharyngeal Carcinoma (NPC): EBV-Specific CTL Responses in the Blood and Tumors of NPC Patients and the Antigen-Processing Function of the Tumor Cells, The Journal of Immunology, vol.165, issue.1, pp.573-582, 2000.
DOI : 10.4049/jimmunol.165.1.573

D. Chua, J. Huang, B. Zheng, S. Lau, W. Luk et al., Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma, International Journal of Cancer, vol.59, issue.1, pp.73-80, 2001.
DOI : 10.1002/ijc.1430

C. Lin, W. Lo, T. Lee, Y. R. Hwang, S. Cheng et al., Immunization with Epstein-Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma, Cancer Res, vol.62, pp.6952-6958, 2002.

D. Budiani, S. Hutahaean, S. Haryana, M. Soesatyo, and W. Sosroseno, Interleukin-10 levels in Epstein-Barr virus-associated nasopharyngeal carcinoma, J Microbiol Immunol Infect, vol.35, pp.365-368, 2002.

K. Straathof, C. Bollard, U. Popat, M. Huls, T. Lopez et al., Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes, Blood, vol.105, issue.5, pp.1898-1904, 2005.
DOI : 10.1182/blood-2004-07-2975

W. Fang, X. Li, Q. Jiang, Z. Liu, H. Yang et al., Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China, Journal of Translational Medicine, vol.6, issue.1, p.32, 2008.
DOI : 10.1186/1479-5876-6-32

N. Mokni-baizig, K. Ayed, F. Ayed, S. Ayed, F. Sassi et al., Association between HLA-A/-B Antigens and -DRB1 Alleles and Nasopharyngeal Carcinoma in Tunisia, Oncology, vol.61, issue.1, pp.55-58, 2001.
DOI : 10.1159/000055353

A. Hildesheim, R. Apple, C. Chen, S. Wang, Y. Cheng et al., Association of HLA Class I and II Alleles and Extended Haplotypes With Nasopharyngeal Carcinoma in Taiwan, CancerSpectrum Knowledge Environment, vol.94, issue.23, pp.1780-1789, 2002.
DOI : 10.1093/jnci/94.23.1780

D. Goldsmith, T. West, and R. Morton, HLA associations with nasopharyngeal carcinoma in Southern Chinese: a meta-analysis, Clinical Otolaryngology and Allied Sciences, vol.10, issue.4, pp.61-67, 2002.
DOI : 10.1002/(SICI)1097-0215(19970422)74:2<229::AID-IJC16>3.0.CO;2-8

M. Yu and J. Yuan, Epidemiology of nasopharyngeal carcinoma, Seminars in Cancer Biology, vol.12, issue.6, pp.421-429, 2002.
DOI : 10.1016/S1044579X02000858

B. Feng, W. Huang, Y. Shugart, M. Lee, F. Zhang et al., Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4, Nature Genetics, vol.31, pp.395-399, 2002.
DOI : 10.1038/ng932

M. Tsai, W. Chen, and F. Tsai, Correlation of p21 gene codon 31 polymorphism and TNF-? gene polymorphism with nasopharyngeal carcinoma, Journal of Clinical Laboratory Analysis, vol.8, issue.3, pp.146-150, 2002.
DOI : 10.1002/jcla.10032

Z. Huang, R. Desper, A. Schaffer, Z. Yin, X. Li et al., Construction of tree models for pathogenesis of nasopharyngeal carcinoma, Genes, Chromosomes and Cancer, vol.108, issue.4, pp.307-315, 2004.
DOI : 10.1002/gcc.20036

A. Chan, P. Teo, and D. Huang, Pathogenesis and treatment of nasopharyngeal carcinoma, Seminars in Oncology, vol.31, issue.6, pp.794-801, 2004.
DOI : 10.1053/j.seminoncol.2004.09.008

C. Lu, J. Chen, S. Tsai, Y. Jin, J. Tsai et al., Nasopharyngeal carcinoma-susceptibility locus is localized to a 132 kb segment containing HLA-A using high-resolution microsatellite mapping, International Journal of Cancer, vol.44, issue.5, pp.742-746, 2005.
DOI : 10.1002/ijc.20946

X. Li, E. Wang, Y. Zhao, J. Ren, J. P. Yao et al., Chromosomal imbalances in nasopharyngeal carcinoma: a metaanalysis of comparative genomic hybridization results, Journal of Translational Medicine, vol.4, issue.1, p.4, 2006.
DOI : 10.1186/1479-5876-4-4

X. Li, N. Ghandri, D. Piancatelli, S. Adams, D. Chen et al., Associations between HLA Class I alleles and the prevalence of nasopharyngeal carcinoma (NPC) among Tunisians, Journal of Translational Medicine, vol.5, issue.1, p.22, 2007.
DOI : 10.1186/1479-5876-5-22

J. Ioannidis, E. Ntzani, and T. Trikalinos, 'Racial' differences in genetic effects for complex diseases, Nature Genetics, vol.66, issue.12, pp.1312-1318, 2004.
DOI : 10.1038/35052543

R. Huang, S. Duan, E. Kistner, W. Zhang, W. Bleibel et al., Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans, Pharmacogenetics and Genomics, vol.18, issue.6, pp.545-549, 2008.
DOI : 10.1097/FPC.0b013e3282fe1745

A. Kurian and K. Cardarelli, Racial and ethnic differences in cardiovascular disease risk factors: a systematic review, Ethn Dis, vol.17, pp.143-152, 2007.

W. Zhang, S. Duan, W. Bleibel, S. Wisel, R. Huang et al., Identification of common genetic variants that account for transcript isoform variation between human populations, Human Genetics, vol.2, issue.1, pp.81-93, 2009.
DOI : 10.1007/s00439-008-0601-x

M. Morley, C. Molony, T. Weber, J. Devlin, K. Ewens et al., Genetic analysis of genome-wide variation in human gene expression, Nature, vol.2, issue.7001, pp.743-747, 2004.
DOI : 10.1159/000072312

B. Stranger, M. Forrest, A. Clark, M. Minichiello, S. Deutsch et al., Genome-Wide Associations of Gene Expression Variation in Humans, PLoS Genetics, vol.12, issue.6, p.78, 2005.
DOI : 10.1371/journal.pgen.0010078.sg003

B. Stranger, A. Nica, M. Forrest, A. Dimas, C. Bird et al., Population genomics of human gene expression, Nature Genetics, vol.142, issue.10, pp.1217-1224, 2007.
DOI : 10.1038/ng2142

S. Tishkoff and K. Kidd, Implications of biogeography of human populations for 'race' and medicine, Nature Genetics, vol.63, issue.11s, pp.21-27, 2004.
DOI : 10.1038/ng1438

C. Lengauer, K. Kinzler, and B. Vogelstein, Genetic instabilities in human cancers, Nature, vol.396, issue.6712, pp.643-649, 1998.
DOI : 10.1038/25292

D. Liu, O. Day, S. Yang, D. Boasberg, P. Milford et al., Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study, Clin Cancer Res, vol.11, pp.1237-1246, 2005.

H. Gogas, J. Ioannovich, U. Dafni, C. Stavropoulou-giokas, K. Frangia et al., Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon, New England Journal of Medicine, vol.354, issue.7, pp.709-718, 2006.
DOI : 10.1056/NEJMoa053007

J. Kirkwood, A. Tarhini, M. Panelli, S. Moschos, H. Zarour et al., Next Generation of Immunotherapy for Melanoma, Journal of Clinical Oncology, vol.26, issue.20, pp.3445-3455, 2008.
DOI : 10.1200/JCO.2007.14.6423

H. Yamaguchi, R. Calado, H. Ly, S. Kajigaya, G. Baerlocher et al., the Gene for Telomerase Reverse Transcriptase, in Aplastic Anemia, New England Journal of Medicine, vol.352, issue.14, pp.1413-1424, 2005.
DOI : 10.1056/NEJMoa042980

Z. Xin, A. Beauchamp, R. Calado, J. Bradford, J. Regal et al., Functional characterization of natural telomerase mutations found in patients with hematologic disorders, Blood, vol.109, issue.2, pp.524-532, 2007.
DOI : 10.1182/blood-2006-07-035089

R. Calado and N. Young, Telomere maintenance and human bone marrow failure, Blood, vol.111, issue.9, pp.4446-4455, 2008.
DOI : 10.1182/blood-2007-08-019729

P. Gaglio, M. Rodriguez-torres, R. Herring, B. Anand, T. Box et al., Racial Differences in Response Rates to Consensus Interferon in HCV Infected Patients Naive to Previous Therapy, Journal of Clinical Gastroenterology, vol.38, issue.7, pp.599-604, 2004.
DOI : 10.1097/00004836-200408000-00012

H. Conjeevaram, M. Fried, L. Jeffers, N. Terrault, T. Wiley-lucas et al., Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1, Gastroenterology, vol.131, issue.2, pp.470-477, 2006.
DOI : 10.1053/j.gastro.2006.06.008

X. Su, L. Yee, K. Im, S. Rhodes, Y. Tang et al., Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C, Journal of Hepatology, vol.49, issue.2, pp.184-191, 2008.
DOI : 10.1016/j.jhep.2008.04.011

J. Kelly, J. Kelley, K. Kaufman, J. Kilpatrick, G. Bruner et al., Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans, Genes and Immunity, vol.54, issue.3, pp.187-194, 2008.
DOI : 10.1038/gene.2008.4

B. Namjou, A. Sestak, D. Armstrong, R. Zidovetzki, J. Kelly et al., High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups, Arthritis & Rheumatism, vol.4, issue.4, pp.1085-1095, 2009.
DOI : 10.1002/art.24387

G. Ahlenstiel, H. Nischalke, K. Bueren, T. Berg, M. Vogel et al., The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients, Journal of Hepatology, vol.47, issue.3, pp.348-355, 2007.
DOI : 10.1016/j.jhep.2007.04.008

C. Sarrazin, T. Berg, V. Weich, T. Mueller, U. Frey et al., GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection, Journal of Hepatology, vol.43, issue.3, pp.388-393, 2005.
DOI : 10.1016/j.jhep.2005.03.020

S. Tishkoff, F. Reed, F. Friedlaender, C. Ehret, A. Ranciaro et al., The Genetic Structure and History of Africans and African Americans, Science, vol.324, issue.5930, 2009.
DOI : 10.1126/science.1172257

T. Wallace, R. Prueitt, M. Yi, T. Howe, J. Gillespie et al., Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men, Cancer Research, vol.68, issue.3, pp.927-936, 2008.
DOI : 10.1158/0008-5472.CAN-07-2608

D. Martin, B. Boersma, M. Yi, M. Reimers, T. Howe et al., Differences in the Tumor Microenvironment between African-American and European-American Breast Cancer Patients, PLoS ONE, vol.64, issue.2, p.4531, 2009.
DOI : 10.1371/journal.pone.0004531.s005

A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu et al., Cancer Statistics, 2008, Cancer statistics, pp.71-96, 2008.
DOI : 10.3322/CA.2007.0010

R. Weichselbaum, H. Ishwaran, T. Yoon, D. Nuyten, S. Baker et al., An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer, Proceedings of the National Academy of Sciences, vol.105, issue.47, pp.18490-18495, 2008.
DOI : 10.1073/pnas.0809242105

E. Engels, X. Wu, J. Gu, Q. Dong, J. Liu et al., Systematic Evaluation of Genetic Variants in the Inflammation Pathway and Risk of Lung Cancer, Cancer Research, vol.67, issue.13, pp.6520-6527, 2007.
DOI : 10.1158/0008-5472.CAN-07-0370

D. Leibovici, H. Grossman, C. Dinney, R. Millikan, S. Lerner et al., Polymorphisms in Inflammation Genes and Bladder Cancer: From Initiation to Recurrence, Progression, and Survival, Journal of Clinical Oncology, vol.23, issue.24, pp.5746-5756, 2005.
DOI : 10.1200/JCO.2005.01.598

P. Ascierto and J. Kirkwood, Adjuvant therapy of melanoma with interferon: lessons of the past decade, Journal of Translational Medicine, vol.6, issue.1, p.62, 2008.
DOI : 10.1186/1479-5876-6-62

J. Kirkwood and A. Tarhini, Biomarkers of Therapeutic Response in Melanoma and Renal Cell Carcinoma: Potential Inroads to Improved Immunotherapy, Journal of Clinical Oncology, vol.27, issue.16, pp.2583-2585, 2009.
DOI : 10.1200/JCO.2008.21.1540

Z. Yurkovetsky, J. Kirkwood, H. Edington, A. Marrangoni, L. Velikokhatnaya et al., Multiplex Analysis of Serum Cytokines in Melanoma Patients Treated with Interferon-??2b, Clinical Cancer Research, vol.13, issue.8, pp.2422-2428, 2007.
DOI : 10.1158/1078-0432.CCR-06-1805

C. Soubrane, R. Mouawad, and O. Rixe, Changes in circulating VEGF- A levels related to clinical response during biochemotherapy in metastatic malignant melanoma, J Clin Oncol, vol.22, p.717, 2004.

C. Soubrane, O. Rixe, J. Meric, D. Khayat, and R. Mouawad, Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study, Melanoma Research, vol.15, issue.3, pp.199-204, 2005.
DOI : 10.1097/00008390-200506000-00009

G. Phan, P. Attia, S. Steinberg, D. White, and S. Rosenberg, Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma, Journal of Clinical Oncology, vol.19, issue.15, pp.3477-3482, 2001.
DOI : 10.1200/JCO.2001.19.15.3477

S. Moschos, H. Edington, S. Land, U. Rao, D. Jukic et al., Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumor Regression in Association With Modulation of Tumor Infiltrating Host Cellular Immune Responses, Journal of Clinical Oncology, vol.24, issue.19, pp.3164-3171, 2006.
DOI : 10.1200/JCO.2005.05.2498

M. Atkins, M. Regan, D. Mcdermott, J. Mier, E. Stanbridge et al., Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer, Clinical Cancer Research, vol.11, issue.10, pp.3714-3721, 2005.
DOI : 10.1158/1078-0432.CCR-04-2019

M. Panelli, E. Wang, and F. Marincola, The Pathway to Biomarker Discovery: Carbonic Anhydrase IX and the Prediction of Immune Responsiveness, Clinical Cancer Research, vol.11, issue.10, pp.3601-3603, 2005.
DOI : 10.1158/1078-0432.CCR-05-0475

F. Hodi, M. Mihm, R. Soiffer, F. Haluska, M. Butler et al., Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients, Proceedings of the National Academy of Sciences, vol.100, issue.8, pp.4712-4717, 2003.
DOI : 10.1073/pnas.0830997100

C. Doehn, T. Bohmer, I. Kausch, M. Sommerauer, and D. Jocham, Prostate Cancer Vaccines, BioDrugs, vol.41, issue.14S, pp.71-84, 2008.
DOI : 10.2165/00063030-200822020-00001

K. Lassi and N. Dawson, Emerging therapies in castrate-resistant prostate cancer, Current Opinion in Oncology, vol.21, issue.3, pp.260-265, 2009.
DOI : 10.1097/CCO.0b013e32832a1868

M. Jinushi, Y. Nakazaki, M. Dougan, D. Carrasco, M. Mihm et al., MFG-E8???mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF, Journal of Clinical Investigation, vol.117, issue.7, pp.1902-1913, 2007.
DOI : 10.1172/JCI30966DS1

M. Jinushi, Y. Nakazaki, D. Carrasco, D. Draganov, N. Souders et al., Milk Fat Globule EGF-8 Promotes Melanoma Progression through Coordinated Akt and Twist Signaling in the Tumor Microenvironment, Cancer Research, vol.68, issue.21, pp.8889-8898, 2008.
DOI : 10.1158/0008-5472.CAN-08-2147

M. Jinushi, F. Hodi, and G. Dranoff, Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines, Immunological Reviews, vol.169, issue.1, pp.287-298, 2008.
DOI : 10.1084/jem.20051848

M. Aloysius, M. Kechnie, A. Robins, R. Verma, C. Eremin et al., Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs, Journal of Translational Medicine, vol.7, issue.1, p.18, 2009.
DOI : 10.1186/1479-5876-7-18

T. Tatsumi, L. Kierstead, E. Ranieri, L. Gesualdo, F. Schena et al., MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma, Clin Cancer Res, vol.9, pp.947-954, 2003.

E. Hawk, L. Matrisian, W. Nelson, G. Dorfman, L. Stevens et al., The Translational Research Working Group Developmental Pathways: Introduction and Overview, Clinical Cancer Research, vol.14, issue.18, pp.5664-5671, 2008.
DOI : 10.1158/1078-0432.CCR-08-1268

M. Cheever, J. Schlom, L. Weiner, H. Lyerly, M. Disis et al., Translational Research Working Group Developmental Pathway for Immune Response Modifiers, Clinical Cancer Research, vol.14, issue.18, pp.5692-5699, 2008.
DOI : 10.1158/1078-0432.CCR-08-1266

M. Cheever, J. Allison, A. Ferris, O. Finn, B. Hastings et al., The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research, Clinical Cancer Research, vol.15, issue.17, 2009.
DOI : 10.1158/1078-0432.CCR-09-0737

N. Sato, Y. Hirohashi, T. Tsukahara, T. Kikuchi, H. Sahara et al., Molecular pathological approaches to human tumor immunology, Pathology International, vol.133, issue.4, pp.205-217, 2009.
DOI : 10.1111/j.1440-1827.2009.02353.x

H. Wada, E. Sato, A. Uenaka, M. Isobe, R. Kawabata et al., Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination, International Journal of Cancer, vol.56, issue.10, pp.2362-2369, 2008.
DOI : 10.1002/ijc.23810

A. Fields, A. Keller, L. Schwartzberg, S. Bernard, C. Kardinal et al., Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer, Journal of Clinical Oncology, vol.27, issue.12, pp.1941-1947, 2009.
DOI : 10.1200/JCO.2008.18.5710

M. Chaudry, K. Sales, P. Ruf, H. Lindhofer, and M. Winslet, EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges, British Journal of Cancer, vol.5, issue.2, pp.1013-1019, 2007.
DOI : 10.1016/j.humpath.2003.08.026

C. Volpers, C. Thirion, V. Biermann, S. Hussmann, H. Kewes et al., Antibody-Mediated Targeting of an Adenovirus Vector Modified To Contain a Synthetic Immunoglobulin G-Binding Domain in the Capsid, Journal of Virology, vol.77, issue.3, pp.2093-2104, 2003.
DOI : 10.1128/JVI.77.3.2093-2104.2003

I. Hoshino, H. Matsubara, N. Hanari, M. Mori, T. Nishimori et al., Histone Deacetylase Inhibitor FK228 Activates Tumor Suppressor Prdx1 with Apoptosis Induction in Esophageal Cancer Cells, Clinical Cancer Research, vol.11, issue.21, pp.7945-7952, 2005.
DOI : 10.1158/1078-0432.CCR-05-0840

L. Shen, M. Toyota, Y. Kondo, E. Lin, L. Zhang et al., Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer, Proceedings of the National Academy of Sciences, vol.104, issue.47, pp.18654-18659, 2007.
DOI : 10.1073/pnas.0704652104

H. Suzuki, M. Toyota, Y. Kondo, and Y. Shinomura, Inflammation-Related Aberrant Patterns of DNA Methylation: Detection and Role in Epigenetic Deregulation of Cancer Cell Transcriptome, Methods Mol Biol, vol.512, pp.55-69, 2009.
DOI : 10.1007/978-1-60327-530-9_5